Navigation Links
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Date:10/3/2007

stekinumab would represent a much needed addition in the treatment armamentarium."

About the PHOENIX 2 Trial

The Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis Followed by Long-term Extension 2 (PHOENIX 2) trial involved 1,230 patients with chronic plaque psoriasis. Patients were randomized to receive subcutaneously administered ustekinumab or placebo. Patients randomized to receive ustekinumab received 45 mg or 90 mg doses at weeks 0 and 4 followed by the same dose every 12 weeks. Patients in the placebo group crossed over to receive either 45 mg or 90 mg doses of ustekinumab at weeks 12 and 16 and every subsequent 12 weeks. The primary end point of the study was the proportion of patients who achieved PASI 75 at week 12.

Through week 12, the placebo-controlled portion of the study, the percentages of study participants who experienced at least one adverse event (AE) were comparable between the placebo group (49 percent) and the ustekinumab 45 mg group (53 percent) and 90 mg group (48 percent). Discontinuation due to an AE occurred in 0.2 percent and one percent of patients in the respective ustekinumab groups, compared with two percent of patients in the placebo group. Two percent and one percent of patients receiving 45 mg or 90 mg ustekinumab, respectively, experienced at least one serious AE compared with two percent of patients receiving placebo.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease that results from inflammation in the skin and overproduction of skin cells that accumulate on the surface causing red, scaly plaques that may itch and bleed. This chronic inflammation is driven in part by IL-12 and IL-23, cytokines involved in the regulation of the body's immune response. It is estimated that 125 million people worldwide have psoriasis, including two percent of
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... CHAPEL HILL, N.C. , Aug. 28, 2015 ... critical market research projects can slow down the ... costs. It is, therefore, absolutely critical for biopharmaceutical ... the market research approval process for quicker and ... recent research by Best Practices, LLC, nearly three-quarters ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Pranoprofen ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma ... as an inflammatory drug, pranoprofen was later developed ... under the trade name of pranopulin for the ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... 2010 Genomic Health, Inc. (Nasdaq: GHDX ) today ... 30, 2010. Total revenue increased to $46.3 million in ... third quarter of 2009.  Product revenue was $45.8 million in the ... $38.9 million in the third quarter of 2009. ...
... Nov. 8, 2010 PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly dividend of $.12 per share ...  The dividend will be payable December 15, 2010, to shareholders ... public in 1984 Mesa Labs has maintained strong cash positions ...
Cached Medicine Technology:Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 2Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 3Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 4Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 5Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 6Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 7Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 8
(Date:8/29/2015)... ... August 29, 2015 , ... "I ... from Miller Place, N.Y. "I specialize in manual therapy, and my invention will ... can be used for additional muscle dysfunction throughout the body." , They developed ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... mesothelioma develops, may extend and improve the lives of patients, according to a ... Click here to read the full article. , The authors of ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik ... zero standard shipping costs. , “Before, a threshold of $49.00 was required to qualify ... and items qualify for free standard shipping for customers regardless of the item’s selling ...
(Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... the Ganesh Shanker Vidyarthi Memorial (GSVM) Medical College have ... // in bringing medical knowledge and technology that would ... ,The two institutes have signed a memorandum ... increased collaboration on several fronts. ,The heads ...
... Association (AMA) says that the federal budget has poorly ... for not addressing problems like obesity //and indigenous health. ... develop world-first medical technologies to fight cancer and heart ... for the National Health and Medical Research Council by ...
... Japanese Encephalitis immunisation which was initially scheduled to take ... 15. //The Uttar Pradesh government is responsible for the ... dates. Japanese Encephalitis is the main reason for the ... Statistics show that in UP alone about 600-700 children ...
... of fungal infection in Bausch and Lomb lens wearers are ... association arrived at is that nearly 50% of those who ... solution, manufactured by Bausch and Lomb. ,Bausch & ... solution, feels that the cause of Fusarium keratitis infection is ...
... study, drinking tap water increases the risk of bladder cancer. ... if one drink too much of it may be a ... published in the April 15 issue of International Journal of ... based drinks each day increased the risk of bladder cancer ...
... Research (ICAR) has identified Indira Kankoda I (RMF 37), ... Chhattisgarh, Uttar Pradesh, Jharkhand, Orissa and Maharashtra. ... will be the first spine gourd variety identified for ... vegetable crop locally known as Meetha Karela, Khekhsa, Padora ...
Cached Medicine News:
... Lyphochek Fertility Control ... monitor the clinically significant ... most frequently assayed during ... Elevated hCG and hCG-Beta ...
Liquichek Spinal Fluid Control is a liquid, bilevel product designed to monitor the performance of automated and manual procedures for the analysis of proteins and other critical analytes assayed in ...
The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
... Nucleic Sample Preparation Platform provides flexible, automated ... platform can prepare up to 96 patient ... and one half-hours, and performs onboard quantitation ... 30 minutes each. Based on Beckman ...
Medicine Products: